What Is Nonadherence In Community Psychiatry

By taking the time and educating ourselves, we are eliminating possible misconceptions about the illness. Working with people that have a mental disorder is the best way to understand how and why they act the way they do. While the cause of schizophrenia is still unknown, it is believed that both genetics and environmental factors play a role. Schizophrenia consists of five subtypes; paranoid, disorganized, catatonic, undifferentiated, and residual. Symptoms can range from hallucinations to delusions, and disorganized thinking. Since there is no cure for schizophrenia, treatment is aimed at controlling the positive, negative, and cognitive symptoms. By starting with a single antipsychotic medication and evaluating the efficacy in four to six weeks, they are able to determine if that medication will work or if they need to try a different one. Once they find out what works, they must adhere to it. Through improved public awareness society can break the pervasive stigma and discrimination surrounding mental illnesses that stand in the way of finding cures and help people with schizophrenia lead full lives they

The primary schizophreniform disorder treatment is medication; however, compliance is a major problem. People with schizophreniform disorder often go off their medication for long periods during their lives and ensuring that the patient continues with medication is the key to successful treatment. Martin is a typical patient with schizophreniform disorder in that he does not have insight into his condition and, as a result, does not believe he is sick. Martin’s parents have tried to get him to go with them to a psychiatrist for an evaluation, but Martin refuses. This contributes to his non-compliance with medication. The medication can help control a patient 's hallucinations and delusions, but it cannot help them to learn to

Rather than seeing a rise in aggressive behavior, a substantial decrease in such behaviors was noted:

Medications are a necessity in dealing with this illness. Anti-psychotics are predominant in the copious amounts of prescriptions that are written for the diagnosed. My experience in the school setting, summer proves to be a season for change as parents use this time to stop or change dosages of medications without doctor advice or approval. Although “regular classes” are not in session, summer school classes can be faced as a challenge when necessary medications have not been taken. I have learned at my practicum site, adult patients in the clinic have taken to self-medicating, adding in marijuana and other street drugs, either in addition or instead of the doctor prescribed medications. Removing one or more drugs from the cocktail that the doctor prescribed can create a windfall of problems for the patients. In stopping and restarting anti-psychotic medication, the patient runs the risk of relapse of symptoms, sometimes worse than they were

Individuals with Schizophrenia typically use medications to treat his or her symptoms. This paper will examine one newspaper article about research conducted by scientists at the National Institute of Mental Health and three peer-reviewed journal articles. This will be done in order to investigate if Cognitive-behavioral therapy (CBT) aids in minimizing symptoms of Schizophrenia more effectively with medication, without medication, and in combination with other therapy styles. These articles propose that CBT should be examined with caution in order to comprehend how it impacts Schizophrenic symptoms. The effectiveness of CBT and reduction of Schizophrenic symptoms could differ in each individual. This is due to numerous factors such as, socioeconomic status, gender, race, environment, family history, and exposure to drugs. It is important to be aware that with every scientific study that is conducted, there may be errors within the study. This may be due to how the data was collected.

Medication is an important treatment for individuals with schizophrenia disorder. Antipsychotics, mood stabilizers and antidepressants are the most popular for treating these individuals (Rubin, Springer, & Trawver, 2010). Because their treatment revolves around medication to help stabilize them, it is important to set up behavioral tailoring interventions. Behavioral tailoring involves cues that remind the individual to take their medication, usually paired with routines (Rubin, Springer, & Trawver, 2010). These routines could be anything from teeth rushing to brushing your hair, and involve set reminders to take the medication (Rubin, Springer, & Trawver, 2010). The adherence to taking the medication has a long-term improvement on their disorder (Rubin, Springer, & Trawver, 2010). Although this is only effective with

As we have seen, treatment of schizophrenia with antipsychotic drugs can have impressive results in terms of decreasing active symptoms, although it does nothing to alleviate negative symptoms or to improve cognitive functioning. Unfortunately, this kind of treatment has the drawback of extremely serious and even fatal side-effects. Newer generation atypical antipsychotics offer more hope, as they can treat both active and negative symptoms, and also improve cognitive functioning. Moreover, they have fewer side-effects. However, treatment is complicated by the fact that results are unpredictable; and in addition the side-effects that they do have can be very serious, such as diabetes, which in itself is life-threatening. However, as the potential side-effects are known, the physician has leeway to choose a drug which is a good match for the patient’s clinical profile. Then, once the patient’s symptoms have been much alleviated with an appropriate newer generation atypical antipsychotic, the patient should be able to also benefit from a range of psychotherapeutic interventions. It is argued that this is the best treatment regime to choose, as it is likely to result in the greatest improvement in quality of life, coupled with the lowest risk of potentially devastating side-effects, or of death. This is likely to be better than utilizing cognitive behavioral therapy, the results of which are not reliably known – although research has certainly shown that it is less efficacious

Within mental health and illness there is a vast amount of treatment options, medications and interventions to treat numerous psychotic disorders. A somewhat controversial treatment within the mental health field, known as long acting injectable antipsychotics (LAIAs), will be discussed in this argumentative paper. Evidence will be presented on how effective LAIA medication is, when compared to oral forms of antipsychotic medication, and the strengths and limitations of administering them. Perceptions of LAIAs from the view of nurses, health professionals and consumers, as well as the nurse’s role in administering and promoting recovery orientated care for people with a mental illness will also be covered. This essay will not provide a clear view, for or against LAIAs, but rather support both positives and negatives of the use of this medication within the mental health field.

Interventions ideally should be long-term and include a range of psychosocial approaches, including cognitive behavioral therapy, conflict management, and substance abuse treatment. However, this sort of idyllic treatment may be increasingly difficult to accomplish in the real world, given reductions in reimbursements for mental health services, ever-shorter hospital stays, inadequate discharge planning, fragmented care in the community, and lack of options for patients with a dual diagnosis. The Schizophrenia Patient Outcomes Research Team (PORT) guidelines, for example, outlined the type of multimodal treatment necessary to increase chances of full recovery. Most patients with schizophrenia do not obtain the kind of treatment outlined in the PORT guidelines. Answers to these challenges will arise not from clinicians, but from policy makers. (Siever, L

Some reasons for non-adherence are common across all types of illnesses. These include side effects, cost, forgetfulness, and not feeling the need to take the drug (Wegmann, n.d.). Adherence rates decrease even more when an illness is chronic, in part due to the additional complexities of these illnesses. Multifaceted treatment regimens, multiple physician involvement, and lack of understanding about medications are common reasons for this increase in non-adherence. Moreover, people who have chronic illnesses often feel that they do not need medication when they are feeling asymptomatic (Brown & Bussells, 2011). Chronic psychiatric disorders, especially severe ones, can come with their own reasons for non-adherence. These can include anosognosia (an unawareness or denial of a neurological deficit), and feeling “enslaved” to the medication (Colom et al., 2005). Even the very nature of bipolar disorder can lead to noncompliance. Both the seductive nature of mania, and the apathy of depression can lend themselves toward medication non-adherence (Black Dog Institute, 2013). In fact, 90% of people with bipolar disorder have seriously considered stopping their medication therapy at some time during their life (Colom et al., 2005). Given the multitude of reasons listed above, is not surprising that bipolar disorder has

Schizophrenia is a life-long disorder that affects about one percent of the population (Mueser & McGurk, 2004). The cause of this mental illness is still unclear. Studies have suggested that Schizophrenia does not arise from one factor but from a combination of genetic, environmental, and social factors (Liddle, 1987). People diagnosed with Schizophrenia struggle to deal with a multitude of symptoms that make it difficult to function (Mueser & McGurk, 2004). Antipsychotic medications are a popular treatment of the symptoms of Schizophrenia (Mueser & McGurk, 2004). Research is constantly being done to develop these medications to enhance the quality of life of those diagnosed with Schizophrenia.

“Treatment has been revealed to be effective in minimizing the symptoms and in helping the person better cope with the disorder and improve social functioning” (Yogewary, 2014). Treatment for schizoaffective disorder can be categorized as pharmacologic and non-pharmacologic. It is shown that 87 percent of those treated for schizoaffective disorder use a combination of pharmacologic agents. Such agents include antipsychotics, antidepressants and mood stabilizers. In fact, 93 percent of those diagnosed with schizoaffective disorder receive antipsychotics (Buckley, Cascade, Kalali, 2009). “Antipsychotic medications are an effective treatment for schizoaffective disorder for most, but not all, persons with this disorder. These drugs are not a “cure” for the disorder, but they can reduce symptoms and prevent relapses among the majority of people with the disorder” (“Facts About Schizoaffective”, n.d.). Lithium, a major mood stabilizer, is an important treatment. It can not only treat mania, but also prevent manic and depressive

Nordentoft et al. (2013) gathered 547 individuals ranging from 18 to 45 years old and were selected via a central-randomized trial, which basically involves randomly selecting individuals that will be placed in either a control group or experimental group. Criterion for diagnosis consisted of individuals “within the schizophrenic spectrum” (Nordentoft et al., 2013, p. 2), who did not take antipsychotic medication for as long as 12 weeks. Assessment of treatment involved recurring interviews at 1, 2, and 5 years. Interview test batteries that were used were the Schedule for Clinical Assessment in Neuropsychiatry, Scales for Assessment of Positive (and Negative) Symptoms, Global Assessment of Functioning, the Social Network Schedule, plus the Interview for Retrospective Assessment of Onset of Schizophrenia, Social Behavior Assessment Schedule, and Client Satisfaction Questionnaire

Clearly, this is a very serious disorder, which is often utterly incapacitating. Therefore, individuals urgently require efficacious treatment, both for survival and for quality of life, and many different kinds of treatment and therapy are used. This paper will examine the use of two of these, cognitive behavioral therapy and drug therapy, and evaluate which one is better. It will take the position that drug therapy is a more effective therapy for treating schizophrenia than is cognitive behavioral therapy.

Intervention: Influence of medication reminder packaging (Automatic Pill Dispenser) on schizophrenic adult patients’ medication adherence behavior.